Large-scale data on the hepatitis D virus (HDV)/hepatitis B virus (HBV) co-infection rate is needed to estimate the current ...

China has made significant progress in reducing mother-to-child transmission of hepatitis B, but further efforts are needed ...

Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline –– Interim ...

The 34th annual meeting of the Asian-Pacific Association for the Study of the Liver is scheduled to take place in Beijing ...

Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline - - Interim Phase 1b proof-of-concept data, including initial efficacy ...

Strategic transformation ongoing, positioning the Company as a focused leader in immunology and inflammatory diseasesHighly differentiated, ...

Announced first in vivo clinical validation for ARCUS gene editing across two distinct programs including wholly owned PBGENE-HBV and partnered program ECUR-506 - - Commenced Phase 1 ELIMINATE-B ...

Chronic Hepatitis B (VTP-300 ... safety and efficacy of VTP-850 in men with rising prostate-specific antigen after definitive local therapy for prostate cancer (i.e., biochemical recurrence) are ...

As the life sciences, medtech, and diagnostic industries continue to expand and grow increasingly complex, so does the legal, regulatory, ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where ...